Pharmaceuticals

Xembify Market 2026 growing with subcutaneous immunoglobulin demand

March 27, 2026March 27, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Xembify Market Between 2026 And 2030?

The historical growth can be linked to higher diagnosis rates for primary immunodeficiency diseases, broader access to plasma-derived therapies, increased awareness among healthcare professionals, the expansion of specialized immunology clinics, and enhanced cold chain distribution capabilities.

The projected growth in the forecast period is driven by a rising incidence of chronic immune conditions, a heightened demand for self-administered treatments, the expansion of homecare infusion offerings, increasing investments in plasma collection infrastructure, and continuous progress in immunoglobulin formulation science.

Key trends observed in the forecast period encompass a greater uptake of subcutaneous immunoglobulin therapies, a growing inclination towards home-based immunoglobulin administration, an intensifying focus on patient-centric treatment guidelines, the enlargement of long-term immunodeficiency management solutions, and enhancements in stability alongside formulation advancements.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20419&type=smp

What Drivers Are Influencing The Xembify Market?

The increasing occurrence of Primary Immunodeficiency Diseases (PI) is anticipated to propel the expansion of the xembify market. These diseases involve conditions where the immune system is weak or absent, hindering the body’s defense against infections and making individuals more prone to sickness. The higher prevalence of Primary Immunodeficiency Diseases (PI) can be attributed to enhancements in diagnostic methods, greater understanding and acknowledgment of these ailments, more advanced genetic testing, and improved identification of previously undetected instances. Xembify plays a vital role in treating PI by providing immunoglobulin therapy, which strengthens the immune system and leads to better patient results. As an illustration, a report released in August 2023 by Thermo Fisher, a US-based life science and clinical research firm, estimated that roughly 6 million people worldwide suffer from a primary immunodeficiency (PID), with approximately 5,000 individuals in the UK affected by this condition. Consequently, the growing prevalence of Primary Immunodeficiency Diseases (PI) is projected to fuel the growth of the xembify market.

Which Market Segments Are Examined In The Xembify Market Study?

The xembify market covered in this report is segmented –

1) By Indication: Primary Immunodeficiency, Secondary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barré Syndrome, Immune Thrombocytopenia (ITP), Multifocal Motor Neuropathy (MMM)

2) By Distribution Channel: Direct Sales, Pharmacies, Online Retailers

3) By End User: Hospitals, Clinics, Homecare Settings

Which Trends Are Influencing The Xembify Market?

A notable trend in the xembify market involves the expansion of indications, such as those for the 20% subcutaneous immunoglobulin (SCIg) product, aiming to offer more adaptable dosing choices for individuals with primary immunodeficiency and other immune-related ailments. The 20% subcutaneous immunoglobulin (SCIg) product serves as a medication for treating primary immunodeficiency and additional immune-related conditions, supplying a concentrated form of immunoglobulin G (IgG) administered through subcutaneous injection to bolster the immune system. For example, in July 2024, Grifols, S.A., a Spain-based pharmaceutical and chemical manufacturer, obtained approval from the U.S. Food and Drug Administration (FDA) for an extended label for its 20% subcutaneous immunoglobulin (SCIg) product, XEMBIFY, to cover treatment-naïve patients with primary humoral immunodeficiencies (PI). This endorsement established XEMBIFY as the initial 20% SCIg therapy deliverable without prior intravenous treatment, affording patients increased flexibility and convenience. This accomplishment highlights Grifols’ dedication to bettering patient outcomes by delivering groundbreaking and patient-centric immunoglobulin therapies.

Who Are The Primary Competitors In The Xembify Market?

Major companies operating in the xembify market are Grifols S.A.

Read the full xembify market report here:

https://www.thebusinessresearchcompany.com/report/xembify-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Xembify Market?

North America was the largest region in the xembify market in 2025. The regions covered in the xembify market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Xembify Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20419&type=smp

Browse Through More Reports Similar to the Global Xembify Market 2026, By The Business Research Company

Industrial X Ray Market Report 2026

https://www.thebusinessresearchcompany.com/report/industrial-x-ray-global-market-report

Xylene Market Report 2026

https://www.thebusinessresearchcompany.com/report/xylene-global-market-report

Xylitol Market Report 2026

https://www.thebusinessresearchcompany.com/report/xylitol-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795